Decitabine

COVID-19: the growth of telemedicine, oral agents and disruptions in clinical trial operations

State-of-the-art treatment regimens for LR-MDS

Sorafenib maintenace improves outcomes for FLT3-ITD AML

Sabatolimab plus HMAs in high-/very high-risk MDS and ND-AML

Glasdegib plus low-dose cytarabine for elderly AML patients who have failed HMAs

Novel therapies on the horizon for MDS

Post-transplant maintenance for patients with AML

Prolonging remission in AML

TP53-mutant AML linked to poorer outcomes with decitabine plus venetoclax

Cytoreductive therapy is safe and feasible for newly-diagnosed AML

Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246

MDS: managing HMA failure

The 2021 MDS armamentarium

Phase Ib/II trial of quizartinib, decitabine and venetoclax in FLT3-ITD-mutated AML

MRD negativity predicts improved survival in AML

Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML